PCSK9 inhibitor alleviates experimental pulmonary fibrosis-induced pulmonary hypertension via attenuating epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling in vivo and in vitro

PCSK9 inhibitor alleviates experimental pulmonary fibrosis-induced pulmonary hypertension via attenuating epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling in vivo and in vitro

BackgroundThe co-occurrence of pulmonary hypertension (PH) in patients with pulmonary fibrosis (PF) is linked to a more unfavorable prognosis and increased mortality compared to PF cases without PH. Early intervention and comprehensive management are pivotal for improving survival outcomes. Proprote...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Jiancheng Lin, Zetao Pan, Jiayan Sun, Xiaowan Wang, Di Yin, Cunyang Huo, Qiang Guo
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Frontiers Media S.A. 2024-12-01
Sarja:Frontiers in Medicine
Aiheet:
pulmonary fibrosis
pulmonary hypertension
PCSK9
EMT
Wnt
β-catenin
Linkit:https://www.frontiersin.org/articles/10.3389/fmed.2024.1509168/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2024.1509168/full

Samankaltaisia teoksia